Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

TheGreedyGrinch Jul. 14 at 11:15 PM

$AKBA Hey bulls, y'all remember these days?

0 · Reply

aansari115 Jul. 14 at 9:25 PM

$AKBA we need to all roo, roo, roo like the Norway team

2 · Reply

Mr_Pithy Jul. 14 at 8:07 PM

$AKBA GREEN BIKINI ON A GREEN DAY. GOOD LUCK ☘️

1 · Reply

asavasir Jul. 14 at 7:48 PM

$AKBA have any one see the GREADYGREENCH 🤓

2 · Reply

Akba_BO Jul. 14 at 7:47 PM

$AKBA Take a run at the 200 starting next week ✅

0 · Reply

Invest2live Jul. 14 at 7:02 PM

$CPIX 318% already; congrats 🔆🌷🌿 Checkout $AKBA and $RXRX

0 · Reply

ZacksResearch Jul. 14 at 6:50 PM

$AKBA Gains 24.6% in the Month So Far 💰 A series of positive updates boosted investor sentiment 🔥 Will the rally continue? See what Wall Street expects next 👉 https://www.zacks.com/stock/research/AKBA/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38785&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38785

0 · Reply

roomza Jul. 14 at 6:49 PM

$AKBA iis it happy meal time already??? lol

1 · Reply

Mr_Pithy Jul. 14 at 6:04 PM

$AKBA SIMPLY WALL ST., $77.29 FAIR VALUE. GOOD LUCK ☘️ TO ALL OF US.

2 · Reply

Mr_Pithy Jul. 14 at 5:59 PM

$AKBA AROON INDICATOR - BULLISH SIGNAL. BULLISH MOVE SET UP. BUY THE STOCK. GOOD LUCK ☘️.

0 · Reply

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-30T12:31:42.000Z - 14 days ago

Akebia announces VOICE trial met predefined stopping criteria

Jun 30, 2026, 8:00 AM EDT - 14 days ago

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Jun 17, 2026, 10:00 AM EDT - 27 days ago

Akebia Therapeutics Transcript: AGM 2026

2026-06-10T12:28:51.000Z - 4 weeks ago

Akebia announces new Vafseo patent

Jun 10, 2026, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Jun 4, 2026, 7:35 AM EDT - 5 weeks ago

Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 6 weeks ago

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 7, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

May 4, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Proxy statement: Proxy filing

2026-04-13T12:52:17.000Z - 3 months ago

Akebia doses first participants in AKB-9090 trial

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

Apr 2, 2026, 10:00 AM EDT - 3 months ago

Akebia Therapeutics Transcript: R&D Day 2026

Apr 2, 2026, 10:00 AM EDT - 3 months ago

Akebia Therapeutics Slides: FY 2026

Apr 1, 2026, 4:05 PM EDT - 3 months ago

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Mar 19, 2026, 4:05 PM EDT - 4 months ago

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

Mar 9, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

Feb 27, 2026, 6:00 AM EST - 4 months ago

Akebia Therapeutics Slides: Corporate presentation

Feb 26, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

2026-02-25T12:25:29.000Z - 4 months ago

Akebia price target lowered to $4 from $5 at BTIG

Feb 19, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Feb 12, 2026, 9:30 AM EST - 5 months ago

Akebia Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-06T11:56:25.000Z - 5 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler

Feb 4, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12T13:52:21.000Z - 6 months ago

Akebia announces corporate updates, 2026 pipeline outlook

Jan 12, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

2026-01-06T13:22:48.000Z - 6 months ago

Akebia announces first patient dosed in Phase 2 trial of praliciguat

Jan 6, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Dec 2, 2025, 4:30 PM EST - 8 months ago

Akebia Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-01T12:21:08.000Z - 8 months ago

Akebia Therapeutics announces establishment of rare kidney disease pipeline

QTTB

2025-12-01T12:11:17.000Z - 8 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront

QTTB

2025-12-01T12:05:21.000Z - 8 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB

Dec 1, 2025, 7:00 AM EST - 8 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 8 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Nov 24, 2025, 8:00 AM EST - 8 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:00 AM EST - 8 months ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 3:00 PM EST - 8 months ago

Akebia Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:00 AM EST - 8 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Akebia Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

Akebia Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 6:30 PM EST - 8 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 4, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

2025-10-30T10:11:16.000Z - 9 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-28T20:45:13.000Z - 9 months ago

Akebia says not in alignment with FDA on path forward for VALOR clinical trial

Oct 28, 2025, 4:30 PM EDT - 9 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 9 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Sep 8, 2025, 12:00 PM EDT - 11 months ago

Akebia Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:05 PM EDT - 11 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-08-21T12:21:04.000Z - 11 months ago

Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 13, 2025, 1:30 PM EDT - 11 months ago

Akebia Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

2025-08-04T12:15:36.000Z - 1 year ago

Akebia initiates post-marketing study to identify benefits of Vafseo

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 14, 2025, 10:00 AM EDT - 1 year ago

Akebia Therapeutics Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 8:45 AM EDT - 1 year ago

Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 20, 2025, 2:30 PM EDT - 1 year ago

Akebia Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 19, 2025, 10:17 PM EDT - 1 year ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Annual report: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Jan 21, 2025, 7:00 AM EST - 1 year ago

Akebia Therapeutics Slides: Investor Presentation

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Slides: FY 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 1 year ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

TheGreedyGrinch Jul. 14 at 11:15 PM

$AKBA Hey bulls, y'all remember these days?

0 · Reply

aansari115 Jul. 14 at 9:25 PM

$AKBA we need to all roo, roo, roo like the Norway team

2 · Reply

Mr_Pithy Jul. 14 at 8:07 PM

$AKBA GREEN BIKINI ON A GREEN DAY. GOOD LUCK ☘️

1 · Reply

asavasir Jul. 14 at 7:48 PM

$AKBA have any one see the GREADYGREENCH 🤓

2 · Reply

Akba_BO Jul. 14 at 7:47 PM

$AKBA Take a run at the 200 starting next week ✅

0 · Reply

Invest2live Jul. 14 at 7:02 PM

$CPIX 318% already; congrats 🔆🌷🌿 Checkout $AKBA and $RXRX

0 · Reply

ZacksResearch Jul. 14 at 6:50 PM

0 · Reply

roomza Jul. 14 at 6:49 PM

$AKBA iis it happy meal time already??? lol

1 · Reply

Mr_Pithy Jul. 14 at 6:04 PM

$AKBA SIMPLY WALL ST., $77.29 FAIR VALUE. GOOD LUCK ☘️ TO ALL OF US.

2 · Reply

Mr_Pithy Jul. 14 at 5:59 PM

$AKBA AROON INDICATOR - BULLISH SIGNAL. BULLISH MOVE SET UP. BUY THE STOCK. GOOD LUCK ☘️.

0 · Reply

Mr_Pithy Jul. 14 at 5:51 PM

$AKBA JULY 1, 2026, H.C. WAINWRIGHT & CO., REITERATE BUY RATING, MAINTAIN $6.00 PRICE TARGET. 322.535% UPSIDE. GOOD LUCK ☘️ TO US ALL.

0 · Reply

Paperglider Jul. 14 at 5:36 PM

$AKBA I am not sure if there was a follow-up to this agreement between Amgen and Davita after Dec. 31, 2022. Likely not Post-VOCAL study results, hope to see in Q4 top-down Vafseo protocol enforcement agreement with off-invoice discount to DaVita (ESA like pricing) and value-based hospitalization-offset sharing terms. https://www.amgen.com/newsroom/press-releases/2017/01/amgen-and-davita-enter-into-new-sourcing-and-supply-agreement

2 · Reply

PlsStonks Jul. 14 at 5:32 PM

$AKBA

0 · Reply

PharmaExpert Jul. 14 at 4:43 PM

$AKBA bargain price!🔥

0 · Reply

Magic_Money Jul. 14 at 4:30 PM

$AKBA With DaVita’s exclusivity ending any day now with Mircera and with DaVita’s second half launch with observed dosing of V, I expect much better sales numbers in Q3 and even higher in Q4 while they transition to V. I am believing and hoping DaVita ramps up fast.

2 · Reply

HarryA123 Jul. 14 at 2:22 PM

$AKBA is that it??

5 · Reply

Acemaker12 Jul. 14 at 1:49 PM

$AKBA FYI, https://seekingalpha.com/article/4921839-akebia-stock-vafseo-gains-traction-still-a-show-me-story-rating-downgrade?share_source=shared_news

1 · Reply

Tirordinary Jul. 14 at 1:28 PM

$AKBA come on 1.50 this week already

1 · Reply

Paperglider Jul. 14 at 1:23 PM

$AKBA Haven't read the article yet, but worth a read I guess. https://seekingalpha.com/article/4921839?gt=90060e06535239cc

2 · Reply

Tiger10 Jul. 14 at 1:04 PM

$AKBA not implying anything, but interesting to see hardly any PUT volume at the $2.00 strike. 🔮 we trade back in the 1.40’s today.

1 · Reply

Magic_Money Jul. 14 at 1:03 PM

$AKBA Remember Mircera (CSL/Fresenius/Roche) exclusivity ends ~June-August 2026. Will that change their practice? Very well could. If KCAPA is approved, it definitely will. Would be nice to hear something at ER.

1 · Reply

Mr_Pithy Jul. 14 at 11:21 AM

$AKBA TOP TEN TUTE OWNERS OWN ~24.15% OF AKEBIA (~265M shares/~60M+ shares). GOOD LUCK ☘️ TO HONEST INVESTORS.

0 · Reply

Market Cap	375.56M
Revenue (ttm)	236.20M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2.27%
Debt to Equity Ratio	1.79

Volume	2,875,100
Avg Vol	5,677,456
Day's Range	N/A - N/A
Shares Out	268.26M
Stochastic %K	77%
Beta	0.23
Analysts	Strong Sell
Price Target	$4.20